James Thomas Reuberson

USPTO Granted Patents = 17 (Patent Applications = 1)

CIPO Patents = 5 (Patent Applications = 12)

EPO Patents = 12 (Patent Applications = 22)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 85(Granted Patents)

Company Filing History:

Katholieke Universiteit Leuven, Ku Leuven R&d

Celltech Therapeutics Limited

6. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12391688 - Imidazopyridine derivatives as IL-17 modulators (2025-08-19),

2. 11472794 - Fused imidazole derivatives as IL-17 modulators (2022-10-18),

3. RE48622 - Therapeutically active pyrazolo-pyrimidine derivatives (2021-07-05),

4. 10450320 - Hexahydropyrazinotriazinone derivatives as kinase inhibitors (2019-10-22),

5. 10087180 - Pyrazolo-pyridine derivatives as kinase inhibitors (2018-10-02),

6. 10004737 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-06-26),

7. 10000497 - Fused bicyclic heteroaromatic derivatives as kinase inhibitors (2018-06-19),

8. 9969748 - Fused bicyclic heteroaromatic derivatives as kinase inhibitors (2018-05-15),

9. 9815797 - Fused bicyclic heteroaromatic derivatives as modulators of TNF activity (2017-11-14),

10. 9714248 - Therapeutically active pyrazolo-pyrimidine derivatives (2017-07-25),

11. 9550737 - TNF -α modulating benzimidazoles (2017-01-24),

12. 9382263 - Therapeutically active oxazoline derivatives (2016-07-05),

13. 9309243 - Imidazopyridine derivatives as modulators of TNF activity (2016-04-12),

14. 9227984 - Therapeutically active fused pyrimidine derivatives (2016-01-05),

15. 9096614 - Therapeutically active thiazolo-pyrimidine derivatives (2015-08-04),

Title: The Innovative Mind of James Thomas Reuberson

Introduction: James Thomas Reuberson is a prominent inventor based in Slough, GB, recognized for his significant contributions to the field of biomedical research. With a remarkable portfolio of 16 patents, he has established himself as a key player in developing therapeutic solutions for various human ailments.

Latest Patents: Among his latest innovations are two noteworthy patents. The first is focused on "Fused imidazole derivatives as IL-17 modulators," which includes a series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives. These compounds are recognized for their potency in modulating human IL-17 activity, offering potential benefits in treating and preventing inflammatory and autoimmune disorders. The second patent pertains to "Therapeutically active pyrazolo-pyrimidine derivatives," comprising a series of pyrazolo[3,4-d]pyrimidine derivatives. These derivatives, substituted at the 4-position by various structural moieties, show promise in addressing inflammatory, autoimmune, and oncological disorders, as well as combating viral diseases and malaria, and preventing organ and cell transplant rejection.

Career Highlights: Reuberson's career has been marked by his association with leading research organizations, notably UCB Biopharma sprl and Katholieke Universiteit Leuven (KU Leuven R&D). These roles have allowed him to harness his expertise and drive groundbreaking research that culminates in valuable patentable innovations.

Collaborations: Throughout his career, Reuberson has collaborated with notable colleagues such as Helen Tracey Horsley and Daniel James Ford. These collaborations have played a vital role in advancing his research initiatives and enhancing the impact of his inventions.

Conclusion: James Thomas Reuberson's innovative work in the field of biomedical research exemplifies the spirit of invention and creativity. His substantial patent portfolio and collaborative efforts underline his commitment to developing therapies that address pressing medical challenges, ultimately contributing to the betterment of human health.

This text is generated by artificial intelligence and may not be accurate.